Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer
Introduction. Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are “deficiency, dampness, stasis, and toxin,” and Fuzheng–Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2021, Vol.2021, p.4652492-16 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | |
| container_start_page | 4652492 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2021 |
| creator | Shi, Hongshuo Tian, Sisheng Tian, Hu |
| description | Introduction. Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are “deficiency, dampness, stasis, and toxin,” and Fuzheng–Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in the treatment of CRC and also explain from a scientific point of view that FJD multidrug combination can resist “deficiency, dampness, stasis, and toxin.” Methods. We get the composition of FJD from the TCMSP database and get its potential target. We also get the potential target of colorectal cancer according to the OMIM Database, TTD Database, GeneCards Database, CTD Database, DrugBank Database, and DisGeNET Database. Subsequently, PPI analysis, KEGG pathways analysis, and GO biological processes analysis were carried out for the target of FJD in the therapy of colorectal cancer. In addition, we have also built a relevant network diagram. Results. In this study, we identified four core compounds of FJD in the therapy of colorectal cancer, including quercetin, kaempferol, beta-sitosterol, and stigmasterol. At the same time, we also obtained 30 core targets, including STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. FJD treatment of colorectal cancer mainly involves 112 KEGG pathways, including FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, 330 GO biological processes were summarized, including cell proliferation, cell apoptosis, angiogenesis, inflammation, and immune. Conclusions. In this study, we found that FJD can regulate cell proliferation, apoptosis, inflammation and immunity, and angiogenesis through PI3K-Akt signaling pathway to play an anti-CRC effect. |
| doi_str_mv | 10.1155/2021/4652492 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7914091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2499934540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-5fadfd321afd8cd851360ce3c6a7a7b11ebe02f75258a4ccc13e360b1f8c81a93</originalsourceid><addsrcrecordid>eNp9kc2KVDEQhYMozo_uXMsFN4K2k99O7kaQ1tGRQV0oiJtQnVu3O-PtpE1yZxhXvoNv6JOYtttGXbiqgvrqUKcOIfcYfcKYUieccnYip4rLlt8gh0xLNpHcmJv7Xn88IEc5X1DKW631bXIgxNQYocwh-fQGy1VMn5t3S0grcHGIi-vmLBRM64QFio-hiX1zOn5dYlj8-Pb9tcdubJ6ji-7XEBbgQy7NrK4mdAWGZgbBYbpDbvUwZLy7q8fkw-mL97NXk_O3L89mz84nTkpTJqqHru8EZ9B3xnVGMTGlDoWbggY9ZwznSHmvFVcGpHOOCazEnPXGGQatOCZPt7rrcb7CzmEoCQa7Tn4F6dpG8PbvSfBLu4iXVrdM0pZVgYc7gRS_jJiLXfnscBggYByzrZ9tWyGVpBV98A96EccUqr0NJWl9tthQj7eUSzHnhP3-GEbtJjS7Cc3uQqv4_T8N7OHfKVXg0RZY-tDBlf-_3E-z86HO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494042730</pqid></control><display><type>article</type><title>Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Shi, Hongshuo ; Tian, Sisheng ; Tian, Hu</creator><contributor>Lenon, George B. ; George B Lenon</contributor><creatorcontrib>Shi, Hongshuo ; Tian, Sisheng ; Tian, Hu ; Lenon, George B. ; George B Lenon</creatorcontrib><description>Introduction. Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are “deficiency, dampness, stasis, and toxin,” and Fuzheng–Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in the treatment of CRC and also explain from a scientific point of view that FJD multidrug combination can resist “deficiency, dampness, stasis, and toxin.” Methods. We get the composition of FJD from the TCMSP database and get its potential target. We also get the potential target of colorectal cancer according to the OMIM Database, TTD Database, GeneCards Database, CTD Database, DrugBank Database, and DisGeNET Database. Subsequently, PPI analysis, KEGG pathways analysis, and GO biological processes analysis were carried out for the target of FJD in the therapy of colorectal cancer. In addition, we have also built a relevant network diagram. Results. In this study, we identified four core compounds of FJD in the therapy of colorectal cancer, including quercetin, kaempferol, beta-sitosterol, and stigmasterol. At the same time, we also obtained 30 core targets, including STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. FJD treatment of colorectal cancer mainly involves 112 KEGG pathways, including FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, 330 GO biological processes were summarized, including cell proliferation, cell apoptosis, angiogenesis, inflammation, and immune. Conclusions. In this study, we found that FJD can regulate cell proliferation, apoptosis, inflammation and immunity, and angiogenesis through PI3K-Akt signaling pathway to play an anti-CRC effect.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2021/4652492</identifier><identifier>PMID: 33688358</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; AKT1 protein ; Angiogenesis ; Apoptosis ; Cancer ; Cancer therapies ; Cell proliferation ; Chinese medicine ; Colorectal cancer ; Colorectal carcinoma ; Cytokines ; E-cadherin ; Epidermal growth factor ; Epidermal growth factor receptors ; ErbB protein ; ErbB-2 protein ; ESR1 protein ; Forkhead protein ; Gelatinase B ; Genes ; Herbal medicine ; Hyperplasia ; Inflammation ; Insulin-like growth factor I ; Interleukin 6 ; Janus kinase 2 ; Kaempferol ; Kinases ; Lymphocytes T ; Metastasis ; p53 Protein ; Pharmacology ; Proteins ; Signal transduction ; T cell receptors ; Tumor necrosis factor-TNF</subject><ispartof>Evidence-based complementary and alternative medicine, 2021, Vol.2021, p.4652492-16</ispartof><rights>Copyright © 2021 Hongshuo Shi et al.</rights><rights>Copyright © 2021 Hongshuo Shi et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Hongshuo Shi et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-5fadfd321afd8cd851360ce3c6a7a7b11ebe02f75258a4ccc13e360b1f8c81a93</citedby><cites>FETCH-LOGICAL-c448t-5fadfd321afd8cd851360ce3c6a7a7b11ebe02f75258a4ccc13e360b1f8c81a93</cites><orcidid>0000-0003-1989-5361 ; 0000-0003-0012-5869</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914091/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914091/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33688358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Lenon, George B.</contributor><contributor>George B Lenon</contributor><creatorcontrib>Shi, Hongshuo</creatorcontrib><creatorcontrib>Tian, Sisheng</creatorcontrib><creatorcontrib>Tian, Hu</creatorcontrib><title>Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Introduction. Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are “deficiency, dampness, stasis, and toxin,” and Fuzheng–Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in the treatment of CRC and also explain from a scientific point of view that FJD multidrug combination can resist “deficiency, dampness, stasis, and toxin.” Methods. We get the composition of FJD from the TCMSP database and get its potential target. We also get the potential target of colorectal cancer according to the OMIM Database, TTD Database, GeneCards Database, CTD Database, DrugBank Database, and DisGeNET Database. Subsequently, PPI analysis, KEGG pathways analysis, and GO biological processes analysis were carried out for the target of FJD in the therapy of colorectal cancer. In addition, we have also built a relevant network diagram. Results. In this study, we identified four core compounds of FJD in the therapy of colorectal cancer, including quercetin, kaempferol, beta-sitosterol, and stigmasterol. At the same time, we also obtained 30 core targets, including STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. FJD treatment of colorectal cancer mainly involves 112 KEGG pathways, including FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, 330 GO biological processes were summarized, including cell proliferation, cell apoptosis, angiogenesis, inflammation, and immune. Conclusions. In this study, we found that FJD can regulate cell proliferation, apoptosis, inflammation and immunity, and angiogenesis through PI3K-Akt signaling pathway to play an anti-CRC effect.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>AKT1 protein</subject><subject>Angiogenesis</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell proliferation</subject><subject>Chinese medicine</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Cytokines</subject><subject>E-cadherin</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB protein</subject><subject>ErbB-2 protein</subject><subject>ESR1 protein</subject><subject>Forkhead protein</subject><subject>Gelatinase B</subject><subject>Genes</subject><subject>Herbal medicine</subject><subject>Hyperplasia</subject><subject>Inflammation</subject><subject>Insulin-like growth factor I</subject><subject>Interleukin 6</subject><subject>Janus kinase 2</subject><subject>Kaempferol</subject><subject>Kinases</subject><subject>Lymphocytes T</subject><subject>Metastasis</subject><subject>p53 Protein</subject><subject>Pharmacology</subject><subject>Proteins</subject><subject>Signal transduction</subject><subject>T cell receptors</subject><subject>Tumor necrosis factor-TNF</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc2KVDEQhYMozo_uXMsFN4K2k99O7kaQ1tGRQV0oiJtQnVu3O-PtpE1yZxhXvoNv6JOYtttGXbiqgvrqUKcOIfcYfcKYUieccnYip4rLlt8gh0xLNpHcmJv7Xn88IEc5X1DKW631bXIgxNQYocwh-fQGy1VMn5t3S0grcHGIi-vmLBRM64QFio-hiX1zOn5dYlj8-Pb9tcdubJ6ji-7XEBbgQy7NrK4mdAWGZgbBYbpDbvUwZLy7q8fkw-mL97NXk_O3L89mz84nTkpTJqqHru8EZ9B3xnVGMTGlDoWbggY9ZwznSHmvFVcGpHOOCazEnPXGGQatOCZPt7rrcb7CzmEoCQa7Tn4F6dpG8PbvSfBLu4iXVrdM0pZVgYc7gRS_jJiLXfnscBggYByzrZ9tWyGVpBV98A96EccUqr0NJWl9tthQj7eUSzHnhP3-GEbtJjS7Cc3uQqv4_T8N7OHfKVXg0RZY-tDBlf-_3E-z86HO</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Shi, Hongshuo</creator><creator>Tian, Sisheng</creator><creator>Tian, Hu</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1989-5361</orcidid><orcidid>https://orcid.org/0000-0003-0012-5869</orcidid></search><sort><creationdate>2021</creationdate><title>Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer</title><author>Shi, Hongshuo ; Tian, Sisheng ; Tian, Hu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-5fadfd321afd8cd851360ce3c6a7a7b11ebe02f75258a4ccc13e360b1f8c81a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>AKT1 protein</topic><topic>Angiogenesis</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell proliferation</topic><topic>Chinese medicine</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Cytokines</topic><topic>E-cadherin</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB protein</topic><topic>ErbB-2 protein</topic><topic>ESR1 protein</topic><topic>Forkhead protein</topic><topic>Gelatinase B</topic><topic>Genes</topic><topic>Herbal medicine</topic><topic>Hyperplasia</topic><topic>Inflammation</topic><topic>Insulin-like growth factor I</topic><topic>Interleukin 6</topic><topic>Janus kinase 2</topic><topic>Kaempferol</topic><topic>Kinases</topic><topic>Lymphocytes T</topic><topic>Metastasis</topic><topic>p53 Protein</topic><topic>Pharmacology</topic><topic>Proteins</topic><topic>Signal transduction</topic><topic>T cell receptors</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shi, Hongshuo</creatorcontrib><creatorcontrib>Tian, Sisheng</creatorcontrib><creatorcontrib>Tian, Hu</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shi, Hongshuo</au><au>Tian, Sisheng</au><au>Tian, Hu</au><au>Lenon, George B.</au><au>George B Lenon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>4652492</spage><epage>16</epage><pages>4652492-16</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Introduction. Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are “deficiency, dampness, stasis, and toxin,” and Fuzheng–Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in the treatment of CRC and also explain from a scientific point of view that FJD multidrug combination can resist “deficiency, dampness, stasis, and toxin.” Methods. We get the composition of FJD from the TCMSP database and get its potential target. We also get the potential target of colorectal cancer according to the OMIM Database, TTD Database, GeneCards Database, CTD Database, DrugBank Database, and DisGeNET Database. Subsequently, PPI analysis, KEGG pathways analysis, and GO biological processes analysis were carried out for the target of FJD in the therapy of colorectal cancer. In addition, we have also built a relevant network diagram. Results. In this study, we identified four core compounds of FJD in the therapy of colorectal cancer, including quercetin, kaempferol, beta-sitosterol, and stigmasterol. At the same time, we also obtained 30 core targets, including STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. FJD treatment of colorectal cancer mainly involves 112 KEGG pathways, including FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, 330 GO biological processes were summarized, including cell proliferation, cell apoptosis, angiogenesis, inflammation, and immune. Conclusions. In this study, we found that FJD can regulate cell proliferation, apoptosis, inflammation and immunity, and angiogenesis through PI3K-Akt signaling pathway to play an anti-CRC effect.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>33688358</pmid><doi>10.1155/2021/4652492</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-1989-5361</orcidid><orcidid>https://orcid.org/0000-0003-0012-5869</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2021, Vol.2021, p.4652492-16 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7914091 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | 1-Phosphatidylinositol 3-kinase AKT protein AKT1 protein Angiogenesis Apoptosis Cancer Cancer therapies Cell proliferation Chinese medicine Colorectal cancer Colorectal carcinoma Cytokines E-cadherin Epidermal growth factor Epidermal growth factor receptors ErbB protein ErbB-2 protein ESR1 protein Forkhead protein Gelatinase B Genes Herbal medicine Hyperplasia Inflammation Insulin-like growth factor I Interleukin 6 Janus kinase 2 Kaempferol Kinases Lymphocytes T Metastasis p53 Protein Pharmacology Proteins Signal transduction T cell receptors Tumor necrosis factor-TNF |
| title | Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A00%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Network%20Pharmacology%20Interpretation%20of%20Fuzheng%E2%80%93Jiedu%20Decoction%20against%20Colorectal%20Cancer&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Shi,%20Hongshuo&rft.date=2021&rft.volume=2021&rft.spage=4652492&rft.epage=16&rft.pages=4652492-16&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2021/4652492&rft_dat=%3Cproquest_pubme%3E2499934540%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2494042730&rft_id=info:pmid/33688358&rfr_iscdi=true |